# Rat cortex, human plasma

> Easy Peptide follows the GABA experiments — Easy Peptide looks at Selank-related gene expression in rat frontal cortex and enkephalin breakdown in human plasma, without treating either as a task score.

The brain experiment and the plasma assay ask different questions. Their differences are where the interesting work begins.

## Gene expression after Selank

A [rat frontal-cortex experiment](https://pubmed.ncbi.nlm.nih.gov/26924987/) reported changes in the expression of 45 genes at 1 hour after Selank administration and 22 genes at 3 hours. The genes were involved in GABAergic neurotransmission, and the Selank-associated expression changes correlated positively with changes produced by GABA itself.

Those counts look impressively concrete. The larger count refuses to serve as a score for success. These are counts of changed expression at separate times, leaving the practical value of the changes open. Nor do they show that the later set contains only genes from the earlier one.

The interesting observation is the resemblance between the responses to Selank and GABA in this rat tissue. It offers a biological route for further investigation. A claim about useful concentration would still need concentration to be measured.

![Bars compare forty-five changed genes at one hour with twenty-two at three hours](images/cortical-expression.svg)

*Rat frontal cortex: counts of genes with changed expression at separate times. These counts do not describe the direction of every change or the overlap between the sets. [Source experiment](https://pubmed.ncbi.nlm.nih.gov/26924987/).*

## Enkephalins in the plasma assay

A separate [experiment in human plasma in vitro](https://pubmed.ncbi.nlm.nih.gov/11550013/) found that Selank inhibited enzymes that degrade enkephalins. “In vitro” matters here: the work happened in an assay outside a living person. It supports a proposed mechanism involving slower enzymatic breakdown.

The verb inhibited gives the finding a satisfying precision. Something that breaks down a peptide was inhibited in an assay. That is already a substantial laboratory question, before any account of how somebody might feel.

A [related human-serum assay](https://pubmed.ncbi.nlm.nih.gov/11443939/) found inhibition of enkephalin-degrading enzymes with both Selank and Semax. That shared laboratory property invites a comparison of the peptides. I would compare enkephalin degradation first; competing claims about entirely different tasks can wait.

![A technician working with a pipette and a plain assay plate](images/expression-bench.webp)

*Imagined plasma/serum enzyme-assay bench; no named laboratory or actual procedure from the paper is being reconstructed.*

## Changed expression and inhibited breakdown

After these papers, my notes contain two quite different verbs: changed and inhibited. The cortex study describes gene-expression changes; the plasma work describes inhibited enzymatic breakdown. Calling both findings calming would discard the difference that makes each experiment interesting.

The [clinical anxiety report](/anxiety) deserves a separate discussion. Its patients and reported outcomes bring a different kind of information to the question.

---

At Easy Peptide I follow the uneasy meeting of calm and cognition in published research; these essays offer no medical advice.